.png)
~
First time in India : Rusan announces the launch of the Indigenously
Developed APOSAN® 3ml Pen for the Management of OFF Episodes in Patients
with Parkinson’s Disease~
Mumbai,
India | 31st March, 2026 : Rusan Healthcare Pvt. Ltd., the
marketing and distribution arm of Rusan Pharma Limited, an integrated global
pharmaceutical company, has announced the launch of the multi-dose delivery pen
device – APOSAN® 3ml Pen (Apomorphine Hydrochloride solution for injection
in cartridge)(10mg/ml)(3ml pre-filled cartridges) for treatment of motor
fluctuations commonly known as ‘ON-OFF’ episodes in patients suffering from
Parkinson’s disease (PD).
In
2018, Rusan was the first company in India to launch APOSAN® Apomorphine
Hydrochloride solution for injection (10mg/ml) (2ml and 5ml ampoules). Since
APOSAN®’s launch in India, Rusan has observed remarkable clinical impact and
consistently positive patient experiences, underscoring Apomorphine’s value as
a transformative option in Parkinson’s management.
The
company now offers the complete range of Apomorphine Hydrochloride in different
fill volumes namely – 2ml injection, 3ml in pre-filled cartridge with a
‘Multi-dose PEN device’ and 5ml for continuous ‘Infusion PUMPS’ to meet
distinct clinical scenarios in PD management, such as rapid rescue from OFF
episodes using PEN devices and sustained symptom control using infusion PUMPS.
PD
is estimated to affect nearly 10 to 11.7 million people globally, with India
accounting for a significant and growing share of the patient population.
However, the clinical perception is shifting: Early‑Onset Parkinson’s Disease
(EOPD), defined as diagnosis after the age of 20 years and before 50 years, now
represents a growing share of the global burden, with incidence and prevalence
tripling between 1990 and 2021, as reported in the Journal of Neurology, Neurosurgery & Psychiatry 2026. This clearly indicates
that Parkinson’s is not confined to older adults, and the changing age profile
emphasises the importance of increased awareness, early diagnosis and coverage,
to ensure that Parkinson’s care remains accessible across India
The
APOSAN® 3ml PEN offers a multi-dose, dial-a-dose mechanism with an enhanced
dose-visibility window, thereby enabling accurate and consistent dose
administration. The APOSAN® 3ml PEN reduces handling complexity, and supports
safer, more reliable self-administration reducing the risk of dosing errors. The APOSAN® 3ml PEN device’s lightweight, portable
design enables convenient, dependable subcutaneous administration at home,
empowering patients to manage their therapy promptly.
Commenting
on the launch, Ms Malavika Kaura Saxena, Chief Marketing Officer, Rusan
Healthcare, stated, “The APOSAN® 3 ml PEN is a major step forward,
offering a portable, multi-use system for reliable apomorphine delivery.
Complementing this innovation, the APOSAN® HOPE Program
provides structured onboarding, guided
support, and patient-centric services that make advanced rescue therapy easier
to adopt and sustain. By simplifying training, coordination, and day-to-day
therapy management, the APOSAN® HOPE Program helps patients and families use
the therapy with confidence and continuity.”
Also,
commenting on the launch, Dr. Kunal Saxena, Managing Director, Rusan
Pharma Limited, stated, “The launch of APOSAN® 3ml Pen reflects Rusan’s
focused commitment to advancing Parkinson’s care through accessible and
scalable treatment solutions. A defining strength of the brand is Rusan’s fully
integrated manufacturing model. By producing the API internally at its USFDA
& EU GMP accredited facility, the company upholds rigorous quality governance,
reduces reliance on external suppliers, and secures a consistent,
high-integrity supply chain for this critical therapeutic product. Through
innovations like APOSAN® 3ml PEN, we aim to empower patients and caregivers
while continuing to expand access to advanced Parkinson’s care across India.”
ABOUT
APOSAN® HOPE PROGRAM
APOSAN®’s
advanced delivery ecosystem is supported by the APOSAN® HOPE Program. Managed
by Rusan Healthcare, the initiative is designed to equip healthcare
professionals, patients, and caregivers with the training and resources needed
to optimise treatment outcomes for managing OFF episodes. https://aposanhopeprogram.com/
ABOUT
RUSAN HEALTHCARE
Rusan
Healthcare (RHC) Pvt. Ltd., is the dedicated marketing and distribution
arm of Rusan Pharma Limited in India. It focuses on bringing forward innovative
treatments and specialises in the area of Pain management, treatment of
Addiction, Parkinson’s management and critical care. As the customer-facing
entity, RHC bridges the gap between pharmaceutical manufacturing and patient
accessibility and availability across India. By combining the manufacturing
excellence of Rusan Pharma, RHC is committed to expanding the reach of
specialised therapies through innovative technologies such as transdermal
patches, long-acting injectable formulations with a robust distribution
network, making it accessible to patients across India.
